Date updated:04-30-2009
Fast Money's host Melissa Lee spoke with Mike Huckman, CNBC's biotech reporter, to talk about which biotech companies might be good buying opportunities from the swine flu scare. This portfolio also includes some more swine flu plays from the "Fast Money" traders.

-
GSK
Glaxosmithkline P - $41.53
- +0.14%
- $40.95
Huckman mentioned two companies that make anti-virals: GlaxoSmithKline(GKS), which makes Relenza, and Gilead Sciences (GILD), which gets a 20% royalty for Tamiflu, a drug it makes for Roche.

-
GILD
Gilead Sciences - $46.39
- -0.28%
- $46.27
Huckman mentioned two companies that make anti-virals: GlaxoSmithKline(GKS), which makes Relenza, and Gilead Sciences (GILD), which gets a 20% royalty for Tamiflu, a drug it makes for Roche.

-
BAX
Baxter Intl Inc - $54.33
- -1.13%
- $54.71
On the vaccine side, companies like GlaxoSmithKline, Baxter(BAX) and Crucell (CRXL) stand to benefit, Huckman said.

-
CRXL
Crucell Nv - $21.62
- +0.79%
- $21.42
On the vaccine side, companies like GlaxoSmithKline, Baxter(BAX) and Crucell (CRXL) stand to benefit, Huckman said.

-
V
Visa Inc. - $80.00
- -0.22%
- $79.72
JPMorgan on Monday wrote that "concerns over the swine flu outbreak could weigh on MasterCard (MA) and Visa (V) shares due to fears that cross-border fees may suffer from reduced cross-border travel."Najarian said it might be great opportunity to get into credit card issuers like Visa (V) and Mastercard (MA) if the overselling continues tomorrow. He said Visa would be particularly attractive below $55.

-
MA
Mastercard Inc - $231.16
- +0.47%
- $229.74
JPMorgan on Monday wrote that "concerns over the swine flu outbreak could weigh on MasterCard (MA) and Visa (V) shares due to fears that cross-border fees may suffer from reduced cross-border travel."Najarian said it might be great opportunity to get into credit card issuers like Visa (V) and Mastercard (MA) if the overselling continues tomorrow. He said Visa would be particularly attractive below $55.

-
PAC
Grupo Aeroportuar - $27.80
- +2.81%
- $26.75
It seems to me that the market was looking for a reason to sell, explained Karen Finerman. And with the swine flu, they found it. But I think it's a tempest in a pot of tea. I’m looking at Grupo Aeroportuario del Pacifico (PAC), a firm that operates airports in Mexico. It could be time to get long.

-
MAR
Marriot Int Cl A - $26.13
- -1.02%
- $26.37
If you’re looking for swine flu plays, I think Smithfield (SFD) still has upside but Marriott (MAR) is a sell, says Adami.
- Top Professional Portfolios
- 1. Fidelity Contrafund - ...
- 2. Navellier & Associ...
- 3. Calamos Advisors
- 4. Argus Management
- 5. Bernard L. Madoff Inve...
- show all
- Top Do-It-Yourself Portfolios
- » Joseph Russell Portfolio 1
- » Albo's First Portfolio
- » Darrell Werth Portfolio 1
- » Echo5Joker's Portfolio
- » jgroov Portfolio 1
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
Not a Stockpickr member? Join the community today -- for free.Regardless of why a stock is in the news, it never hurts to hear what a professional investor has to say about...
By Roberto Pedone Posted on Nov. 20, 2009 According to Jim Cramer, options expiration is driving the current market selloff. He pointed out that the only stocks that we...
By Roberto Pedone Posted on Nov. 19, 2009 According to CNBC’s “Fast Money” traders, the stock market is showing no signs of stopping its current bull run. Joe Ter...
By Jonas Elmerraji Posted on Nov. 18, 2009 There are plenty of reasons for stocks to have the attention of short-sellers. Waning financials, a deteriorating business mo...
A. The only one I own : SLX,
too hard pick a winner out all of them
These are some of the stocks mentioned on TheStreet.com TV recently. Click the URL below each stock to watch the videos. more
Here are some of the biggest stocks that made the 52-week high list on Nov. 20, 2009. more
Here is a list of some of the biggest stocks that hit 52-week lows on Nov. 20, 2009. more













Comments not available